Table 2 Antidiabetic Drug use, by trimester, in the cohort of all livebirth pregnancies during 2001–2013 in the MSDD
|  | Use in the 90 Days Before Pregnancy | Any Use During Pregnancy | Any Use, First Trimester | Any Use, Second Trimester | Any Use, Third Trimester |
|---|---|---|---|---|---|
Total unique pregnancies | 1,895,604 (100%) | 1,895,604 (100%) | 1,895,604 (100%) | 1,895,604 (100%) | 1,895,122 (100%) |
Drug Class or Product | |||||
 Use of Any Drug | 38,017 (2.0%) | 82,676 (4.4%) | 40,013 (2.1%) | 35,587 (1.9%) | 63,483 (3.4%) |
 Alpha-Glucosidase Inhibitors | 21 (<0.1%) | 149 (<0.1%) | 19 (< 0.1%) | 24 (<0.1%) | 129 (<0.1%) |
 Amylin Analog | 55 (<0.1%) | 48 (<0.1%) | 46 (<0.1%) | 9 (< 0.1%) | 5 (< 0.1%) |
 Metformin | 30,194 (1.6%) | 32,757 (1.7%) | 29,431 (1.6%) | 15,827 (0.8%) | 9897 (0.5%) |
 Dipeptidyl Peptidase-4 Inhibitors | 226 (< 0.1%) | 242 (< 0.1%) | 227 (< 0.1%) | 87 (< 0.1%) | 50 (< 0.1%) |
 Glucagon-like Peptide-1 Agonists | 403 (<0.1%) | 333 (<0.1%) | 316 (<0.1%) | 77 (<0.1%) | 32 (<0.1%) |
 Meglitinide Analogs | 45 (<0.1%) | 44 (<0.1%) | 43 (<0.1%) | 12 (<0.1%) | 2 (<0.1%) |
 Sulfonylureas – Use of Any Drug | 2018 (0.1%) | 28,240 (1.5%) | 2748 (0.1%) | 6325 (0.3%) | 26,234 (1.4%) |
  Glimepiride | 312 (<0.1%) | 280 (<0.1%) | 255 (<0.1%) | 97 (<0.1%) | 61 (<0.1%) |
  Glipizide | 675 (<0.1%) | 768 (< 0.1%) | 617 (<0.1%) | 316 (<0.1%) | 218 (<0.1%) |
  Glyburide | 976 (0.1%) | 27,269 (1.4%) | 1868 (0.1%) | 5905 (0.3%) | 25,973 (1.4%) |
  Tolazamide | 80 (<0.1%) | 82 (<0.1%) | 82 (<0.1%) | 53 (<0.1%) | 23 (<0.1%) |
 Thiazolidinediones | 965 (0.1%) | 874 (0.1%) | 841 (<0.1%) | 274 (<0.1%) | 123 (<0.1%) |
 Combination Products | 565 (<0.1%) | 633 (<0.1%) | 520 (<0.1%) | 204 (<0.1%) | 155 (<0.1%) |
 Insulin – Any Injectable Insulin | 7351 (0.4%) | 34,476 (1.8%) | 12,289 (0.7%) | 18,028 (0.9%) | 33,447 (1.8%) |
  Rapid-acting | 5842 (0.3%) | 25,959 (1.4%) | 10,074 (0.5%) | 14,602 (0.8%) | 24,705 (1.3%) |
  Intermediate-acting | 1803 (0.1%) | 26,103 (1.4%) | 6607 (0.4%) | 11,824 (0.6%) | 24,745 (1.3%) |
  Long-acting | 2394 (0.1%) | 4834 (0.3%) | 2846 (0.2%) | 2791 (0.2%) | 3436 (0.2%) |
  Other-acting | 598 (<0.1%) | 1556 (0.1%) | 854 (0.1%) | 794 (0.1%) | 976 (0.1%) |